Sean A. McCarthy - 20 Aug 2024 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
CEO, Director
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy
Issuer symbol
CTMX
Transactions as of
20 Aug 2024
Net transactions value
-$17,082
Form type
4
Filing time
22 Aug 2024, 17:58:38 UTC
Previous filing
28 Mar 2024
Next filing
06 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Options Exercise $0 +37,500 +5.9% $0.000000 671,749 20 Aug 2024 Direct F1, F2
transaction CTMX Common Stock Sale $17,082 -13,898 -2.1% $1.23 657,851 20 Aug 2024 Direct F2, F3
holding CTMX Common Stock 93,158 20 Aug 2024 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Performance Stock Units (PSUs) Options Exercise $0 -37,500 -100% $0.000000 0 20 Aug 2024 Common Stock 37,500 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2 Includes 197,500 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.
F4 Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
F5 Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.